Objective: Pancreatic ductal adenocarcinoma is an aggressive tumor with short survival. In this study we aimed to investigate the effect of well-known prognostic parameters on survival in these tumors. Material and Method: A total of 56 pancreatic ductal adenocarcinoma cases diagnosed between 2005 and 2014 were included in the study. Survival data were obtained and histopathological parameters were re-evaluated in each patient. Results: Tumor size (p=0.029), mitotic count (p=0.030), lymph node metastasis (p=0.003), metastatic lymph node ratio (p<0.001) and ampullary invasion (p=0.044) had a statistically significant relationship with survival. However, there was no relationship between survival and tumor grade, lymphovascular and peri...
Pancreatic ductal adenocarcinoma carries a poor prognosis with annual deaths almost matching the rep...
Resection margin status and lymph node (LN) involvement are known prognostic factors for patients wh...
AbstractIntroductionSurvival after a resected pancreatic ductal adenocarcinoma (PDAC) appears to be ...
AIMS AND BACKGROUND: The prognosis after surgical resection for pancreatic cancer has not been clea...
Background: The size of pancreatic ductal adenocarcinoma (PDAC) at diagnosis is an indicator of outc...
Background: Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma ...
Objectives: Pancreatic cancer is an aggressive silent killer with a median survival of a few months....
BackgroundPancreatic ductal adenocarcinoma (PDAC) patients demonstrate highly variable survival with...
The question of how successful we are in predicting pancreatic neuroendocrine tumors (panNET) with p...
Background: Pancreatic ductal adenocarcinoma (PDAC) has poor survival. Current treatments offer litt...
BACKGROUND: Survival after resection of pancreatic adenocarcinoma is poor. Several prognostic fa...
Abstract Background The impact of tumor size on prognosis for surgically treated patients with pancr...
Objective: Pancreatic ductal adenocarcinoma is one of the most malignant types of cancer. This study...
Objective: To explore the role of pancreatic ductal adenocarcinoma (PDAC) size on surgical and survi...
Background: The aim of this study was to validate a new definition of borderline resectable pancreat...
Pancreatic ductal adenocarcinoma carries a poor prognosis with annual deaths almost matching the rep...
Resection margin status and lymph node (LN) involvement are known prognostic factors for patients wh...
AbstractIntroductionSurvival after a resected pancreatic ductal adenocarcinoma (PDAC) appears to be ...
AIMS AND BACKGROUND: The prognosis after surgical resection for pancreatic cancer has not been clea...
Background: The size of pancreatic ductal adenocarcinoma (PDAC) at diagnosis is an indicator of outc...
Background: Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma ...
Objectives: Pancreatic cancer is an aggressive silent killer with a median survival of a few months....
BackgroundPancreatic ductal adenocarcinoma (PDAC) patients demonstrate highly variable survival with...
The question of how successful we are in predicting pancreatic neuroendocrine tumors (panNET) with p...
Background: Pancreatic ductal adenocarcinoma (PDAC) has poor survival. Current treatments offer litt...
BACKGROUND: Survival after resection of pancreatic adenocarcinoma is poor. Several prognostic fa...
Abstract Background The impact of tumor size on prognosis for surgically treated patients with pancr...
Objective: Pancreatic ductal adenocarcinoma is one of the most malignant types of cancer. This study...
Objective: To explore the role of pancreatic ductal adenocarcinoma (PDAC) size on surgical and survi...
Background: The aim of this study was to validate a new definition of borderline resectable pancreat...
Pancreatic ductal adenocarcinoma carries a poor prognosis with annual deaths almost matching the rep...
Resection margin status and lymph node (LN) involvement are known prognostic factors for patients wh...
AbstractIntroductionSurvival after a resected pancreatic ductal adenocarcinoma (PDAC) appears to be ...